Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 17/20 | 0.49 |
| ▸ | METAP1 | P53582 | 8/20 | 0.49 |
| ▸ | REN | P00797 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13347345 | 1.00 | METAP2 (0.49) | METAP2METAP1REN | |
| SCHEMBL8209396 | 1.00 | METAP2 (0.49) | METAP2METAP1REN | |
| SCHEMBL7328407 | 0.95 | METAP2 (0.55) | METAP2METAP1REN | |
| SCHEMBL8175196 | 0.95 | METAP2 (0.55) | METAP2METAP1REN | |
| Hydrochloric Acid SCHEMBL9514519 | 0.93 | METAP2 (0.53) | METAP2METAP1REN | |
| Hydrochloric Acid SCHEMBL9514516 | 0.93 | METAP2 (0.53) | METAP2METAP1REN | |
| SCHEMBL10138824 | 0.93 | METAP2 (0.45) | METAP2METAP1REN | |
| SCHEMBL13430909 | 0.93 | METAP2 (0.45) | METAP2METAP1REN | |
| Hydrochloric Acid SCHEMBL27076653 | 0.91 | METAP2 (0.44) | METAP2METAP1REN | |
| Trifluoroacetic Acid SCHEMBL7327225 | 0.85 | METAP2 (0.50) | METAP2METAP1REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104292130-B | A kind of synthetic method of EBP520 intermediate 2-hydroxyl-3-amino-4-cyclobutyl butanamide hydrochloride | SUZHOU UUGENE BIOPHARMA CO., LTD. (CN) | 2016-04-27 | — | — | CN | claimed |
| CN-104292130-B | A kind of synthetic method of EBP520 intermediate 2-hydroxyl-3-amino-4-cyclobutyl butanamide hydrochloride | SUZHOU UUGENE BIOPHARMA CO., LTD. (CN) | 2016-04-27 | — | — | CN | disclosed |
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| EP-1730142-B1 | NOVEL KETOAMIDES WITH CYCLIC P4'S AS INHIBITORS OF NS3 SERINE PROTEASE OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2011-06-29 | — | — | EP | disclosed |
| EP-1939213-B1 | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORP (US) | 2010-08-25 | — | — | EP | disclosed |
| US-7759499-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2010-07-20 | — | — | US | disclosed |
| EP-1730110-B1 | SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORP (US) | 2010-06-09 | — | — | EP | disclosed |
| US-20100113821-A1 | PREPARATION OF 3-AMINO-3-(CYCLOBUTYLMETHYL)-2-(HYDROXY)-PROPIONAMIDE HYDROCHLORIDE | SCHERING-PLOUGH CORPORATION (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113821-A1 | PREPARATION OF 3-AMINO-3-(CYCLOBUTYLMETHYL)-2-(HYDROXY)-PROPIONAMIDE HYDROCHLORIDE | SCHERING-PLOUGH CORPORATION (US) | 2010-05-06 | — | — | US | disclosed |
| EP-1385870-B1 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2006130686-A2 | HCV PROTEASE INHIBITORS IN COMBINATION WITH FOOD | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2005113581-A1 | SUBSTITUTED PROLINES AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005107745-A1 | AN INHIBITOR OF HEPATITIS C | SCHERING CORPORATION (US) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005087730-A1 | 3,4-(CYCLOPENTYL)-FUSED PROLINE COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087721-A2 | COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087725-A2 | NOVEL COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087731-A1 | SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005085242-A1 | NOVEL KETOAMIDES WITH CYCLIC P4'S AS INHIBITORS OF NS3 SERINE PROTEASE OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005085275-A1 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | SCHERING CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
| WO-2003062265-A2 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113821-A1 | PREPARATION OF 3-AMINO-3-(CYCLOBUTYLMETHYL)-2-(HYDROXY)-PROPIONAMIDE HYDROCHLORIDE | CTRL, DNPEP, DPP3 | METAP2 144/4885METAP1 29/4885REN 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.